AA
CASI

ALPS Advisors’s CASI Pharmaceuticals CASI Stock Holding History

ALPS Advisors’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-23,015
Closed -$661K – 883
2019
Q1 		$661K Buy
23,015
+993
+5% +$34.6K ﹤0.01% 423
2018
Q4 		$885K Buy
22,022
+6,699
+44% +$254K 0.01% 330
2018
Q3 		$716K Buy
15,323
+2,821
+23% +$197K ﹤0.01% 463
2018
Q2 		$1.03M Buy
+12,502
New +$844K 0.01% 331

Other funds holding CASI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ALPS Advisors's CASI Position: Q2 2019 in Review

ALPS Advisors sold out of CASI Pharmaceuticals (CASI) in Q2 2019, closing a stake of 23,015 shares — an estimated $661K sold.

ALPS Advisors first reported a position in CASI in Q2 2018 and held it in 4 quarters. The position peaked at $1.03M in Q2 2018. 50 funds tracked by Wall St. Rank hold CASI as of Q2 2019.

  • ALPS Advisors reported no remaining CASI Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • ALPS Advisors sold 23,015 CASI Pharmaceuticals shares in Q2 2019, an estimated $661K.
  • ALPS Advisors first reported a position in CASI Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • ALPS Advisors's CASI Pharmaceuticals position peaked at $1.03M in Q2 2018.
  • 50 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2019.

Based on ALPS Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.